Point-of-care treatment of focal cartilage defects with selected chondrogenic mesenchymal stromal cells—An in vitro proof-of-concept study

Oliver Petters, Christian Schmidt, Christian Thuemmler, Frank Peinemann, Matthias Zscharnack, Jeremy Somerson, Ronny M. Schulz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Due to the poor self-healing capacities of cartilage, innovative approaches are a major clinical need. The use of in vitro expanded mesenchymal stromal cells (MSCs) in a 2-stage approach is accompanied by cost-, time-, and personnel-intensive good manufacturing practice production. A 1-stage intraoperative procedure could overcome these drawbacks. The aim was to prove the feasibility of a point-of-care concept for the treatment of cartilage lesions using defined MSC subpopulations in a collagen hydrogel without prior MSC monolayer expansion. We tested 4 single marker candidates (MSCA-1, W4A5, CD146, CD271) for their effectiveness of separating colony-forming units of ovine MSCs via magnetic cell separation. The most promising surface marker with regard to the highest enrichment of colony-forming cells was subsequently used to isolate a MSC subpopulation for the direct generation of a cartilage graft composed of a collagen type I hydrogel without the propagation of MSCs in monolayer. We observed that separation with CD271 sustained the highest enrichment of colony-forming units. We then demonstrated the feasibility of generating a cartilage graft with an unsorted bone marrow mononuclear cell fraction and with a characterized CD271 positive MSC subpopulation without the need for a prior cell expansion. A reduced volume of 6.25% of the CD271 positive MSCs was needed to achieve the same results regarding chondrogenesis compared with the unseparated bone marrow mononuclear cell fraction, drastically reducing the number of nonrelevant cells. This study provides a proof-of-concept and reflects the potential of an intraoperative procedure for direct seeding of cartilage grafts with selected CD271 positive cells from bone marrow.

Original languageEnglish (US)
Pages (from-to)1717-1727
Number of pages11
JournalJournal of Tissue Engineering and Regenerative Medicine
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2018
Externally publishedYes

Fingerprint

Point-of-Care Systems
Cartilage
Mesenchymal Stromal Cells
Defects
Grafts
Bone
Hydrogel
Collagen
Hydrogels
Bone Marrow Cells
Monolayers
Cells
Transplants
Collagen Type I
Stem Cells
Chondrogenesis
In Vitro Techniques
Adapalene
Cell Separation
Personnel

Keywords

  • ATMP
  • bone marrow-derived mesenchymal stem cells
  • cartilage
  • cell separation
  • hydrogel
  • mesenchymal stromal cells
  • point-of-care

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Cite this

Point-of-care treatment of focal cartilage defects with selected chondrogenic mesenchymal stromal cells—An in vitro proof-of-concept study. / Petters, Oliver; Schmidt, Christian; Thuemmler, Christian; Peinemann, Frank; Zscharnack, Matthias; Somerson, Jeremy; Schulz, Ronny M.

In: Journal of Tissue Engineering and Regenerative Medicine, Vol. 12, No. 7, 01.07.2018, p. 1717-1727.

Research output: Contribution to journalArticle

Petters, Oliver ; Schmidt, Christian ; Thuemmler, Christian ; Peinemann, Frank ; Zscharnack, Matthias ; Somerson, Jeremy ; Schulz, Ronny M. / Point-of-care treatment of focal cartilage defects with selected chondrogenic mesenchymal stromal cells—An in vitro proof-of-concept study. In: Journal of Tissue Engineering and Regenerative Medicine. 2018 ; Vol. 12, No. 7. pp. 1717-1727.
@article{de8f338580434f19a282b2995ef1ac27,
title = "Point-of-care treatment of focal cartilage defects with selected chondrogenic mesenchymal stromal cells—An in vitro proof-of-concept study",
abstract = "Due to the poor self-healing capacities of cartilage, innovative approaches are a major clinical need. The use of in vitro expanded mesenchymal stromal cells (MSCs) in a 2-stage approach is accompanied by cost-, time-, and personnel-intensive good manufacturing practice production. A 1-stage intraoperative procedure could overcome these drawbacks. The aim was to prove the feasibility of a point-of-care concept for the treatment of cartilage lesions using defined MSC subpopulations in a collagen hydrogel without prior MSC monolayer expansion. We tested 4 single marker candidates (MSCA-1, W4A5, CD146, CD271) for their effectiveness of separating colony-forming units of ovine MSCs via magnetic cell separation. The most promising surface marker with regard to the highest enrichment of colony-forming cells was subsequently used to isolate a MSC subpopulation for the direct generation of a cartilage graft composed of a collagen type I hydrogel without the propagation of MSCs in monolayer. We observed that separation with CD271 sustained the highest enrichment of colony-forming units. We then demonstrated the feasibility of generating a cartilage graft with an unsorted bone marrow mononuclear cell fraction and with a characterized CD271 positive MSC subpopulation without the need for a prior cell expansion. A reduced volume of 6.25{\%} of the CD271 positive MSCs was needed to achieve the same results regarding chondrogenesis compared with the unseparated bone marrow mononuclear cell fraction, drastically reducing the number of nonrelevant cells. This study provides a proof-of-concept and reflects the potential of an intraoperative procedure for direct seeding of cartilage grafts with selected CD271 positive cells from bone marrow.",
keywords = "ATMP, bone marrow-derived mesenchymal stem cells, cartilage, cell separation, hydrogel, mesenchymal stromal cells, point-of-care",
author = "Oliver Petters and Christian Schmidt and Christian Thuemmler and Frank Peinemann and Matthias Zscharnack and Jeremy Somerson and Schulz, {Ronny M.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/term.2699",
language = "English (US)",
volume = "12",
pages = "1717--1727",
journal = "Journal of Tissue Engineering and Regenerative Medicine",
issn = "1932-6254",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Point-of-care treatment of focal cartilage defects with selected chondrogenic mesenchymal stromal cells—An in vitro proof-of-concept study

AU - Petters, Oliver

AU - Schmidt, Christian

AU - Thuemmler, Christian

AU - Peinemann, Frank

AU - Zscharnack, Matthias

AU - Somerson, Jeremy

AU - Schulz, Ronny M.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Due to the poor self-healing capacities of cartilage, innovative approaches are a major clinical need. The use of in vitro expanded mesenchymal stromal cells (MSCs) in a 2-stage approach is accompanied by cost-, time-, and personnel-intensive good manufacturing practice production. A 1-stage intraoperative procedure could overcome these drawbacks. The aim was to prove the feasibility of a point-of-care concept for the treatment of cartilage lesions using defined MSC subpopulations in a collagen hydrogel without prior MSC monolayer expansion. We tested 4 single marker candidates (MSCA-1, W4A5, CD146, CD271) for their effectiveness of separating colony-forming units of ovine MSCs via magnetic cell separation. The most promising surface marker with regard to the highest enrichment of colony-forming cells was subsequently used to isolate a MSC subpopulation for the direct generation of a cartilage graft composed of a collagen type I hydrogel without the propagation of MSCs in monolayer. We observed that separation with CD271 sustained the highest enrichment of colony-forming units. We then demonstrated the feasibility of generating a cartilage graft with an unsorted bone marrow mononuclear cell fraction and with a characterized CD271 positive MSC subpopulation without the need for a prior cell expansion. A reduced volume of 6.25% of the CD271 positive MSCs was needed to achieve the same results regarding chondrogenesis compared with the unseparated bone marrow mononuclear cell fraction, drastically reducing the number of nonrelevant cells. This study provides a proof-of-concept and reflects the potential of an intraoperative procedure for direct seeding of cartilage grafts with selected CD271 positive cells from bone marrow.

AB - Due to the poor self-healing capacities of cartilage, innovative approaches are a major clinical need. The use of in vitro expanded mesenchymal stromal cells (MSCs) in a 2-stage approach is accompanied by cost-, time-, and personnel-intensive good manufacturing practice production. A 1-stage intraoperative procedure could overcome these drawbacks. The aim was to prove the feasibility of a point-of-care concept for the treatment of cartilage lesions using defined MSC subpopulations in a collagen hydrogel without prior MSC monolayer expansion. We tested 4 single marker candidates (MSCA-1, W4A5, CD146, CD271) for their effectiveness of separating colony-forming units of ovine MSCs via magnetic cell separation. The most promising surface marker with regard to the highest enrichment of colony-forming cells was subsequently used to isolate a MSC subpopulation for the direct generation of a cartilage graft composed of a collagen type I hydrogel without the propagation of MSCs in monolayer. We observed that separation with CD271 sustained the highest enrichment of colony-forming units. We then demonstrated the feasibility of generating a cartilage graft with an unsorted bone marrow mononuclear cell fraction and with a characterized CD271 positive MSC subpopulation without the need for a prior cell expansion. A reduced volume of 6.25% of the CD271 positive MSCs was needed to achieve the same results regarding chondrogenesis compared with the unseparated bone marrow mononuclear cell fraction, drastically reducing the number of nonrelevant cells. This study provides a proof-of-concept and reflects the potential of an intraoperative procedure for direct seeding of cartilage grafts with selected CD271 positive cells from bone marrow.

KW - ATMP

KW - bone marrow-derived mesenchymal stem cells

KW - cartilage

KW - cell separation

KW - hydrogel

KW - mesenchymal stromal cells

KW - point-of-care

UR - http://www.scopus.com/inward/record.url?scp=85049692301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049692301&partnerID=8YFLogxK

U2 - 10.1002/term.2699

DO - 10.1002/term.2699

M3 - Article

VL - 12

SP - 1717

EP - 1727

JO - Journal of Tissue Engineering and Regenerative Medicine

JF - Journal of Tissue Engineering and Regenerative Medicine

SN - 1932-6254

IS - 7

ER -